Suche klinische Studie
Weitere Suchoptionen
107 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Abgeschlossene Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; Studie unter Beteiligung von ERN-Mitgliedern aus mindestens zwei Mitgliedstaaten = 
Nationale klinische Studie(n)
NIEDERLANDE
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors - UK
Institution: Information not provided - UK
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie-Oncologie thoracique
BELGIEN
NAMUR
YVOIR
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma - BE
Cliniques Universitaires UCL de Mont-Godinne
Department of Hematology
BELGIEN
OOST-VLAANDEREN
GENT
Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer - BE
Universitair ziekenhuis Gent (UZ Gent)
Department of Gastrointestinal Surgery
CHINA
CHINA
ADDRESS: NOT PROVIDED - CN
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Institution: Information not provided - CN
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
CHARLY: Eine Studie zum Stellenwert von Cyclophosphamid nach Thiotepa-Basierter Haplo-identer Stammzelltransplantation für refraktäre non-Hodgkin Lymphome
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
FRANKREICH
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma - FR
Hospices Civils de Lyon - Hôpital Lyon Sud
Service d'hématologie clinique
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A + CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression -FR
Institution: Information not provided - FR
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT
ITALIEN
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O.C. Oncoematologia, Trapianto Emopoietico e Terapie Cellulari
ITALIEN
LOMBARDIA
MILANO
A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial
Fondazione IRCCS Istituto Nazionale dei Tumori
S.S. Oncologia Medica Gastroenterologica
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
RADIANCE: Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma - A multicenter, randomized, phase II trial of the German Anal Cancer Study Group - AT
Institution: Information not provided - AT
PORTUGAL
NORTE
PORTO
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Instituto Português de Oncologia do Porto Francisco Gentil, EPE - IPO Porto, EPE
Serviço de Onco-Hematologia - IPO Porto, EPE
PORTUGAL
SUL
LISBOA
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Centro Hospitalar Universitário Lisboa Norte, EPE - CHULN, EPE
Serviço de Hematologia e Transplantação de Medula
PORTUGAL
SUL
LISBOA
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE
Departamento de Hematologia
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
REDIRECT: A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
KILT: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
VALENTINE-PTCL01: Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants -ES
Institution: Information not provided - ES
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
AVAIL-T: A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Oxfordshire
OXFORD
RomiCar - Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
Churchill Hospital
Department of Haematology
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy- BE
Hôpital Universitaire de Bruxelles (H.U.B) - Site Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIEN
VLAAMS BRABANT
LEUVEN
INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
NAVIGATOR: A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors - FR
CLCC Léon Bérard
Cancérologie médicale - Gynécologie médicale, Tumeurs rares de l'ovaire
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
ImadGist : A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
CLCC Léon Bérard
Cancérologie médicale - Sarcomes et GIST, Tumeurs rares
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
GIST-TEN: Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs) -FR
CLCC Léon Bérard
Centre Léon Bérard
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
GRID: A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for p
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MK-6482-015: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
LILLE
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmen - FR
CLCC Oscar Lambret
Département de cancérologie générale
FRANKREICH
HAUTS-DE-FRANCE
LILLE
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment - BE
CLCC Oscar Lambret
Département de cancérologie générale
FRANKREICH
ILE-DE-FRANCE
PARIS
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy - FR
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière
Service d'oncologie médicale
FRANKREICH
ILE-DE-FRANCE
VILLEJUIF
Phase II Study of Oral AB1010 (Masitinib) in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
CLCC Institut Gustave Roussy
Département de Médecine oncologique - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
CYCLIGIST: Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
ALT GIST: A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) - FR
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
PESSAC
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment - FR
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service d'hématologie et thérapie cellulaire
ITALIEN
PUGLIA
SAN GIOVANNI ROTONDO
Randomized study in open at active control of IIIb phase, of Sunitinib vs Imatinib in the treatment of patients with metastasized gastrointestinal tumor whose disease is evolved under treatment of Imatinib
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
U.O. di Oncologia
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal Tumors who have Received Treatment with Prior Anticancer Therapies-CA
Institution: Information not provided - CA
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Onkologie
OSTERREICH
WIEN
WIEN
An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Onkologie
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene (Phase III) - CH
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment - CH
Institution: Information not provided - CH
SPANIEN
Cataluña
BADALONA
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study -ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Oncología Médica
SPANIEN
Cataluña
BARCELONA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene -ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPANIEN
Cataluña
BARCELONA
SeliGIST: A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) -ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPANIEN
Cataluña
L'HOSPITALET DE LLOBREGAT
ALT GIST: A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) - ES
ICO Hospitalet - Hospital Duran i Reynals
ICO Hospitalet
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Intrigue: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
POD1UM-303/InterAACT 2: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
MK-6482-015: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Peak: A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors - ES
Institution: Information not provided - ES
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene. -GB
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
CAMN107A2409: An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - UK
Addenbrooke's Hospital
Addenbrookes Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
CAMN107A2409: An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - UK
Royal Marsden Hospital
Section of Medicine
VEREINIGTES KONIGREICH
Greater London
SURREY
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy -GB
The Royal Marsden
Royal Marsden NHS Foundation Trust
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Institution: Information not provided - UK
FRANKREICH
BOURGOGNE-FRANCHE-COMTE
DIJON
BALLAD : Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma - FR
CHU Dijon Bourgogne - Hôpital François Mitterrand
Service d'hépato-gastroentérologie
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Glasgow
GLASGOW
A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma - GB
Beatson West of Scotland Cancer Centre
VEREINIGTES KONIGREICH
Greater London
LONDON
A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours - UK
St Bartholomew's Hospital, Barts and The London NHS Trust
Centre for Endocrinology
Multinationale klinische Studie(n)
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
SONNET: Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study
Institution: Information not provided - FR
VEREINIGTE STAATEN
California
LOS ANGELES
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Children's Hospital Los Angeles
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
VEREINIGTE STAATEN
New Jersey
RAHWAY
KEYNOTE 158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors
Merck, Sharp & Dohme Corp.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (Coordination)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy (Coordination)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression.
Institution: Information not provided - US
AUSTRALIEN
Victoria
ADDRESS: NOT PROVIDED - AU
ALT GIST: A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
Institution: Information not provided - AU
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib
Institution: Information not provided - BE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
GRID: A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib
Institution: Information not provided - DE
FRANKREICH
ILE-DE-FRANCE
PARIS
SCHWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
PAGIST: Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group
Institution: Information not provided - SE
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Single-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib (Coordination)
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib (Coordination)
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV)
Institution: Information not provided - CH
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
REGISTRI: Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST - REGISTRI
GEIS - Grupo Español de Investigación de Sarcomas
VEREINIGTE STAATEN
Delaware
WILMINGTON
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy
Incyte Corporation
VEREINIGTE STAATEN
Kansas
LAWRENCE
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC.
VEREINIGTE STAATEN
Massachusetts
CAMBRIDGE
NAVIGATOR: A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
VEREINIGTE STAATEN
Texas
DALLAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene.
Arog Pharmaceuticals, Inc.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma (Coordination)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
MK-6482-015: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
Institution: Information not provided - US
FRANKREICH
ILE-DE-FRANCE
RUEIL-MALMAISON
A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours
Advanced Accelerator Applications SA
Advanced Accelerator Applications
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB